3.3 Associations of supportive therapy with long-term survival
Figure 3 demonstrates the association between each supportive therapy
and survival times in the PAH patients reported in the JADER database.
The PAH patients with oxygen therapy had significantly longer survival
than non-user patients (p = 0.004). The median survival times
(95% CI) of the PAH patients with oxygen therapy and the non-users were
10.04 years (6.19–NA) and 6.01 years (4.75–6.32), respectively. The
PAH patients with concomitant use of epoprostenol and warfarin had
slightly shorter survival compared with the PAH patients treated with
only epoprostenol. In the epoprostenol users, the median survival times
(95% CI) of the PAH patients treated with warfarin and non-warfarin
users were 8.41 years (NA–NA) and 10.04 years (6.21–NA), respectively.
In the non-epoprostenol users, the median survival times (95% CI) of
the PAH patients treated with warfarin and non-warfarin users were 6.30
years (4.09–NA) and 5.00 years (3.95–6.30), respectively. A
significant difference was not observed between the PAH patients treated
with DOAC and non-DOAC users (p = 0.089). The median survival
times (95% CI) of the DOAC users and the non-users were 4.75 years
(2.23–NA) and 6.26 years (5.55–8.41), respectively. The PAH patients
treated with tolvaptan showed significantly shorter survival than
non-user patients (p < 0.001). The median survival
times (95% CI) of the PAH patients treated with tolvaptan and the
non-user patients were 4.75 years (3.61–6.83) and 6.26 years
(5.55–10.04), respectively.